Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. 1984

E Klinge, and P T Männistö, and R Mäntylä, and J Mattila, and U Hänninen

The pharmacokinetic profile of pipemidic acid was studied in two groups of young healthy volunteers by using a new, sensitive, high-pressure liquid chromatography procedure for quantitation of pipemidic acid in biological fluids. After oral or intravenous administration, the disposition of pipemidic acid may be described as a one- or a two-compartment open model, respectively. Oral bioavailability was 93.1 +/- 11% (mean +/- standard error). After administration of a 100-mg tablet, 13.4 +/- 2.7% was bound to serum proteins at the time of peak drug concentration in serum. Excretion of pipemidic acid in saliva was negligible, the saliva/serum ratio being about 0.32. At steady state after the twice-daily administration of a 500-mg tablet, which is a recommended dosage regimen, a peak drug concentration in serum of 4.3 +/- 0.5 micrograms/ml was attained in 1.2 +/- 0.1 h. The apparent volume of distribution was 1.9 +/- 0.2 liters/kg, and the elimination half-life was 3.4 +/- 0.2 h. The renal clearance was 4.3 +/- 0.7 ml/min per kg, and the total clearance was 6.3 +/- 0.5 ml/min per kg. Despite a considerable water load, the minimum concentration in urine at the end of a dosing interval averaged 100 micrograms/ml, which widely exceeds the known MIC of pipemidic acid against bacteria commonly causing urinary tract infections.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D009539 Nicotinic Acids 2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin. Acids, Nicotinic
D010876 Pipemidic Acid Antimicrobial against Gram negative and some Gram positive bacteria. It is protein bound and concentrated in bile and urine and used for gastrointestinal, biliary, and urinary infections. Piperamic Acid,Deblaston,Galusan,Nuril,Palin,Pipram,Urisan,Uropipemid,Acid, Pipemidic,Acid, Piperamic
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

E Klinge, and P T Männistö, and R Mäntylä, and J Mattila, and U Hänninen
May 1993, Journal of clinical pharmacology,
E Klinge, and P T Männistö, and R Mäntylä, and J Mattila, and U Hänninen
December 1987, Journal of clinical pharmacology,
E Klinge, and P T Männistö, and R Mäntylä, and J Mattila, and U Hänninen
January 1988, European journal of clinical pharmacology,
E Klinge, and P T Männistö, and R Mäntylä, and J Mattila, and U Hänninen
September 1986, Fertility and sterility,
E Klinge, and P T Männistö, and R Mäntylä, and J Mattila, and U Hänninen
November 1984, Antimicrobial agents and chemotherapy,
E Klinge, and P T Männistö, and R Mäntylä, and J Mattila, and U Hänninen
June 1992, Antimicrobial agents and chemotherapy,
E Klinge, and P T Männistö, and R Mäntylä, and J Mattila, and U Hänninen
January 1989, Antimicrobial agents and chemotherapy,
E Klinge, and P T Männistö, and R Mäntylä, and J Mattila, and U Hänninen
November 2002, The Journal of antimicrobial chemotherapy,
E Klinge, and P T Männistö, and R Mäntylä, and J Mattila, and U Hänninen
April 1987, Antimicrobial agents and chemotherapy,
E Klinge, and P T Männistö, and R Mäntylä, and J Mattila, and U Hänninen
January 1989, European journal of clinical pharmacology,
Copied contents to your clipboard!